Featured Chrome Extensions:

Casey IRACs are produced by an AI that analyzes the opinion’s content to construct its analysis. While we strive for accuracy, the output may not be flawless. For a complete and precise understanding, please refer to the linked opinions above.

Keywords

appealpatenttrademark
patentappellant

Related Cases

In re Howarth, 654 F.2d 103, 210 U.S.P.Q. 689
View Case »
In re GPAC Inc., 57 F.3d 1573, 35 U.S.P.Q.2d 1116
View Case »
Japanese Foundation for Cancer Research v. Lee, 773 F.3d 1300, 113 U.S.P.Q.2d 1140
View Case »
Merck & Co., Inc. v. Kessler, 80 F.3d 1543, 64 USLW 2668, 38 U.S.P.Q.2d 1347
View Case »
In re Antor Media Corp., 689 F.3d 1282, 103 U.S.P.Q.2d 1555
View Case »
Justia Law Link
LexisNexis Link
Westlaw Link
CourtListener Link
Oyez Link

In re Kubin, 561 F.3d 1351, 90 U.S.P.Q.2d 1417

Facts

The applicants, Marek Kubin and Raymond Goodwin, sought patents for a biotechnology invention related to isolating and sequencing a human gene that encodes a protein known as Natural Killer Cell Activation Inducing Ligand (NAIL). The United States Patent and Trademark Office's Board of Patent Appeals and Interferences rejected their claims, deeming them obvious and invalid due to a lack of written description. The applicants appealed the Board's decision, arguing that their invention was novel and non-obvious.

The specification of the claimed invention recites an amino acid sequence of a NAIL polypeptide. The invention further isolates and sequences a polynucleotide that encodes a NAIL polypeptide.

Issue

Whether the claimed gene sequence for NAIL was unpatentably obvious in light of prior art.

Whether the claimed gene sequence for NAIL was unpatentably obvious in light of prior art.

Rule

Analysis

The Board found that the applicants' claims were unpatentably obvious based on substantial evidence from prior art, including U.S. Patent 5,688,690 and the teachings of Sambrook's laboratory manual. The Board concluded that the methods used by the applicants to isolate the NAIL gene were conventional and well-documented in the prior art. The court affirmed this conclusion, noting that the claimed invention was the product of ordinary skill and common sense, as the prior art provided a reasonable expectation of success in isolating the gene.

The Board found that appellants used conventional techniques 'such as those outlined in Sambrook' to isolate and sequence the gene that codes for NAIL. Id. The Board also found that appellants' claimed DNA sequence is 'isolated from a cDNA library … using the commercial monoclonal antibody C1.7 … disclosed by Valiante.' Id.

Conclusion

The Court of Appeals affirmed the Board's decision, holding that the claimed gene sequence was unpatentably obvious in light of the abundant prior art.

Because the Board correctly determined that appellants' claims are unpatentably obvious, this court affirms.

Who won?

The Board of Patent Appeals and Interferences prevailed in this case, as the Court of Appeals upheld their decision to reject the patent claims. The court found that the Board's conclusion regarding the obviousness of the claimed invention was supported by substantial evidence, including the methodologies outlined in the prior art that the applicants had utilized. The court emphasized that the claimed invention did not represent an innovative leap but rather a straightforward application of known techniques in the field.

You must be